Pharma IQ, a division of IQPC, is an online network and content resource hub designed exclusively for the pharmaceutical industry. The IQ provides its community, standing at over 100,000 members, with complimentary access to an exclusive library of research reports, infographics, news articles, interviews and commentary from leading experts across the world.
Pharma IQ presents the Predictive Toxicology Academy, coming to you this winter.Following a series of successful real world conferences, to aid worldwide accessibility the Predictive Toxicology Academy brings you a hub of online resources all accessible from the comfort of your desk. The Academy will stand as a library hosting a portfolio of various multimedia including live interactive sessions, whitepapers, podcasts, infographics, articles and interviews.
George Clinical – a leading contract research organisation (CRO)in the Asia-Pacific – is now a registered company in South Korea. George Clinical is headquartered in Sydney, Australia and has offices in China, India, Hong Kong, Taiwan, Malaysia, New Zealand, United Kingdom, Czech Republic and the United States.
The George Institute has recently appointed Professor Zhi-Jie Zheng - a prominent researcher and epidemiologist, as the new Executive Director for its operations in China. For over 30 years, Professor Zheng has held senior leadership positions within clinical and public health programs in the United States, such as the Centre for Disease Control and Prevention as well as the National Institute of Health. In addition, Professor Zheng has also served on committees, task forces and workgroups for government agencies in the United States and China.
He will be joined with expert speakers from Medtronic, Edwards Lifesciences, Baxter International, Systelabs, ShoeBar Associates, Neuronetics, GE Healthcare, EndoStim, British Standards Institute, Greatbatch and Lean-Agile Partners this October 26 – 28 in Boston.
(San Francisco, CA.) IQPC’s 19th Software Design for Medical Devices Summit is pleased to announce the chairman of the Summit Mr. Phani Bidarahalli, GM & Head of Healthcare Engineering at Wipro. He will be joined by the expert speaker faculty including senior executive from GE Healthcare, Philips Healthcare, Medtronic and more this May 11 – 12, at The Hotel Kabuki inSan Francisco.
01 May 2015, London, UK - Pharmaceuticals consistently rank within the top ten categories for counterfeit goods and the risk to products can vary from country to country. In response pharmaceutical manufacturers are investing more in product security initiatives, such as serialisation which involves coding products uniquely at the item level.
Office-based healthcare and pharmaceutical workers’ top productivity killers identified in new Regus survey
A recent report by the world’s largest flexible workspace provider Regus has identified the biggest causes of UK healthcare and pharmaceutical professionals’ delays and distractions at work. Of the professionals asked about interruptions to their working day, more than two fifths (43%) identified traffic jams as a productivity killer.
A pioneering new combined cell-gene therapy to treat lung cancer will be tested in NHS patients this year, after receiving £2m of Biomedical Catalyst funding from the Medical Research Council (MRC).
Researchers led by Professor Sam Janes at UCL/UCLH will carry out the first UK clinical trial of a combined stem cell and gene therapy for the disease which kills around 34,000 people a year in the UK.
The treatment uses stem cells as a delivery vehicle for a potent anti-cancer gene, which induces a self-destruct pathway in cancer, but not healthy cells.
Adents, the leading provider of robust and easily deployable software solutions for serialization in the Life Sciences industry, has announced the opening of its second subsidiary in the North American market.
Driven by its firm reputation for successful deployments across Europe and the imminent implementation of the Drug Supply Chain Security Act (DSCSA), Adents today announced the opening of a new wholly owned subsidiary – Adents US Inc.,in Princeton, USA, as the company continues with its major international expansion plan.
System provides nimble, efficient review of multi-centre clinical trials, while maintaining highest ethical standards
A new ‘streamlined’ approach for the ethical review and oversight of multi-centre clinical trials in Ontario was launched today by Clinical Trials Ontario (CTO).
The CTO Streamlined Research Ethics Review System allows any single ‘CTO Qualified’ research ethics board in Ontario to provide ethical review and oversight on behalf of multiple research sites involved in a clinical trial.
A collection of 68 deprioritised pharmaceutical compounds1 is being made available to academic researchers through a partnership between the Medical Research Council (MRC) and seven global drug companies, the largest of its kind in the world.
From today, UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease, which may lead to the development of more effective treatments for a range of conditions.
Medical Research Council (MRC) scientists have created the world’s first enzymes made from artificial genetic material. Their synthetic enzymes, which are made from molecules that do not occur anywhere in nature, are capable of triggering chemical reactions in the lab.
The research, published today in Nature, gives new insights into the origins of life and could provide a starting point for an entirely new generation of drugs and diagnostics.
To respond to the increasing obligation for traceability in the pharmaceutical industry, ADENTS will demonstrate its Pharma Suite solution at the upcoming 5th annual Pharmaceutical Serialisation and Traceability Summit in Geneva from 4th-6th November.
CSafe announced today that it has subcontracted maintenance and repair services for their CSafe RKN at both the Seattle and Dulles International Airports. This notice follows their June announcement of the opening of their CSafe managed service center in San Francisco. The new repair centers at SEA and IAD will service CSafe’s active systems and they anticipate that the growth of these centers will be similar to that of their SFO center.
Pharma giant AstraZeneca is currently leading the way in the development of a new PARP (poly ADP-ribose polymerase) inhibitor for the treatment of ovarian cancer, according to recent analysis by global independent analyst firm Datamonitor Healthcare.
Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three late-stage candidates leading the way, according to independent analyst firm Datamonitor Healthcare.
The NSCLC market in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) is currently worth $7bn, and targeted antibody therapies are expected to see increasing uptake as they continue to demonstrate efficacy against well-defined patient subgroups and reduce systemic toxicity.
Novartis and GlaxoSmithKline have agreed to exchange assets and combine their consumer healthcare units. Novartis has also agreed to sell its animal health division to Lilly for nearly $5.4bn.
Ali Al-Bazergan, analyst at Datamonitor Healthcare said:
“Overall, the flurry of deals makes a lot of sense for all companies involved, unlocking considerable shareholder value. Big Pharma continues to amplify areas of strength whilst divesting non-core assets, a trend that has recently gained traction with successes from Pfizer and Johnson and Johnson.
New Delhi (January 23th, 2014) –4 GS1, a leading global standards organisation, today received accreditation by the U.S. Food and Drug Administration (FDA) as issuing agency for unique device identifiers (UDIs). Global GS1 Standards meet the government’s criteria for UDIs and will help manufacturers to address requirements of the new FDA UDI regulation, which was published in September 2013 to support patient safety and supply chain security.
The growing concern over patient safety is at the heart of every serious discussion among healthcare providers across Asia. According to World Health Organisation (WHO), “nearly one in ten patients is harmed while receiving health care in well-funded and technologically advanced hospital settings”. In less sophisticated hospital settings, the rate could even be higher. Juxtapose this to the fact that many hospitals are also mired in issues such as rising costs, inefficiencies and wastage and you can realise just how big of a problem this is turning out to be.
Government incentives and cost of trials not critical factors
The SAT-EU study group, an independent non-profit collaborative initiative, supported by the European Forum for Good Clinical Practice (EFGCP) and several other trade and not-for profit organisations, today announced the results of a survey of 458 professionals representing clinical research organizations (CROs), academic clinical trial units (CTUs), and the biopharmaceutical industry in 34 countries.
An Ipsos MORI poll commissioned by the Royal Society of Chemistry has shown that 74% of the public believe that a major research and development effort is needed to create new antibiotics for fighting infectious disease.
Ahead of world stroke day on 29th October, independent analysis firm Datamonitor Healthcare has revealed a number of blockbuster drugs, which could transform the way we prevent strokes.
As the second most common cause of death and a major cause of disability worldwide, it is estimated that 15 million people globally suffer a stroke each year, of which 5 million die and 5 million are left permanently disabled.
Jones Lang LaSalle reports the key considerations for transforming existing facilities to meet the rising demand for biologic medicines
Traditional pharmaceutical manufacturing facilities are being driven into dinosaur status as demand grows for biologic and biosimilar production. A new report from Jones Lang LaSalle offers key considerations for re-equipping facilities originally built for traditional chemical medicine production — a process that is anything but minor.
New research from the iOpener Institute for People and Performance, which analyzedresponses from over 30,000 professionals, reveals significant differences between personal productivity levels in different countries and industry sectors. The findings also show a clear relationship between Happiness at Work and personal productivity.